RYSTIGGO
Active substance: rozanolixizumab
INJECTION, SOLUTION · ROZANOLIXIZUMAB 140 mg/mL
United StatesActive
Marketing holder: UCB, Inc.
Verified 2026-10-09 · openFDA NDC
Analogues in other countries- Source: openFDA NDC
- Countries with the substance registered: 2
Composition
- ROZANOLIXIZUMAB · 140 mg/mL
Analogues by country
Products with the same active substance registered in other countries.
| Country | Products |
|---|---|
| EU 1 |
|
Import and control
Control by country
- United Statesprescription only
Source: openFDA NDC · record 01a1208e-6171-7174-b5be-08008f72ff21,01a1208f-cdce-7ea7-b16d-7b155bdd21f4,01a12093-979f-713e-b37d-70616c1717ef,01a12098-bdb4-70a2-b3fa-5daf793d2661;count=4 · valid from 2026-10-09 · verified 2026-10-09
Registration
- Registration number
- 50474-981
- Registration status
- Active
- Dispensing
- Prescription only
- Route
- SUBCUTANEOUS
Sources
- product · openFDA NDC · 50474-981 · Verified 2026-10-09 · open in source
- registration_status · openFDA NDC · 50474-981 · Verified 2026-10-09 · open in source
- ingredients.0 · openFDA NDC · 50474-981 · Verified 2026-10-09 · open in source